Mallinckrodt Celebrates Successful Spinoff from Covidien

Executives and guests of Mallinckrodt Pharmaceuticals, a global company that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents, will visit the New York Stock Exchange (NYSE) to celebrate its successful spinoff and emergence as an independent publicly-traded specialty pharmaceuticals company. To mark this occasion, Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will ring The NYSE Opening Bell, joined by members of the company's management team and new Board of Directors. Covidien will complete the distribution of Mallinckrodt ordinary shares after the close of trading on the New York Stock Exchange (NYSE) on June 28, 2013. On July 1, 2013, regular-way trading will commence on the NYSE for Mallinckrodt under the symbol "MNK" and will continue for Covidien under the symbol "COV." About Mallinckrodt (NYSE: MNK) Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents with the highest quality standards and care. The company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 50 countries and distribution in approximately 40 countries. The company's 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.